A1LN34:BVMF
Alnylam Pharmaceuticals
56,46Â BRL
arrow_upward
+0,21%(+0,12) 1G
14 ott, 12:54:44 GMT-3 · BRL
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per A1LN34 in corso…
Apertura
56,46Â BRL
Massimo
56,46Â BRL
Minimo
56,46Â BRL
Cap. mercato
30,12Â Mld
Vol. medio
495,00
Volume
75,00
Max 52 sett.
132,40Â BRL
Min 52 sett.
50,25Â BRL
Azioni in circolazione
133,81Â Mln
N. di dipendenti
2K
Apertura
56,46Â BRL
Massimo
56,46Â BRL
Minimo
56,46Â BRL
Cap. mercato
30,12Â Mld
Vol. medio
495,00
Volume
75,00
Max 52 sett.
132,40Â BRL
Min 52 sett.
50,25Â BRL
Azioni in circolazione
133,81Â Mln
N. di dipendenti
2K
Articoli giornalistici
Da fonti web e partner giornalistici
Yahoo Finance
·
2 ore fa
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
BioSpace
·
14 ore fa
Alnylam bulls and bears fight it out after business-shaking guidance cut
Investing.com Canada
·
1 giorno fa
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
Investing.com
·
3 giorni fa
Alnylam EVP Bryan Supran sells $398,855 in shares
Profilo
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Informazioni su Alnylam Pharmaceuticals